Last 12 months
Inside the activity.
4 purchase rows · 4 sale rows
Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.Monthly counts
| Month | Purchases | Sales |
|---|---|---|
| Nov 2025 | 2 | 0 |
| Dec 2025 | 1 | 0 |
| Jan 2026 | 0 | 0 |
| Feb 2026 | 0 | 0 |
| Mar 2026 | 0 | 0 |
| Apr 2026 | 0 | 0 |
| May 2026 | 0 | 4 |
| Jun 2026 | 1 | 0 |
| Jul 2026 | 0 | 0 |
| Aug 2026 | 0 | 0 |
| Sep 2026 | 0 | 0 |
| Oct 2026 | 0 | 0 |
Latest available
Insider transactions
Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Owner / reported role | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 26, 2018 Filed Feb 27, 2018 02:15 UTC |
Amezquita AlexanderSVP, Finance & Strat. Planning
|
GrantCommon Stock | 2,665 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-18-013684 · doc4.xml · nonDerivative · entry 1 Amezquita Alexander · CIK 0001721325 · SVP, Finance & Strat. Planning 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,671 F1 · kind: Consists of restricted stock units ("RSU") under the Herbalife Ltd. 2014 Stock Incentive Plan. Each RSU represents a contingent right to receive one share of Herbalife Ltd. common stock on vesting. This award will vest 20% each on February 26, 2019 and February 26, 2020, and 60% on February 26, 2021. Read SEC document |
| February 26, 2018 Filed Feb 27, 2018 02:14 UTC |
Alvarez JesusVP, General Manager, Mexico
|
Exercise / conversionStock Appreciation Rights · Derivative | 1,929 | $0.00 Strike: $79.58 | $0.00 |
DisclosureSEC source: 0001209191-18-013683 · doc4.xml · derivative · entry 8 Alvarez Jesus · CIK 0001615466 · VP, General Manager, Mexico 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,929 shares Expires 2023-12-19 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · kind: The reporting person received 97 shares of common stock upon the net exercise of 1,929 stock appreciation rights ("SARS"). The reporting person forfeited 1,779 shares of common stock underlying the SARS in payment of the exercise price and 53 shares of common stock underlying the SARS to satisfy the withholding tax obligation resulting from the exercise, using the closing stock price on February 26, 2018 of $86.30. Read SEC document |
| February 26, 2018 Filed Feb 27, 2018 02:14 UTC |
Alvarez JesusVP, General Manager, Mexico
|
Tax withholdingCommon Stock | 53 | $86.30 | $4,573.90 |
DisclosureSEC source: 0001209191-18-013683 · doc4.xml · nonDerivative · entry 4 Alvarez Jesus · CIK 0001615466 · VP, General Manager, Mexico 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,182 F2 · kind: The reporting person received 97 shares of common stock upon the net exercise of 1,929 stock appreciation rights ("SARS"). The reporting person forfeited 1,779 shares of common stock underlying the SARS in payment of the exercise price and 53 shares of common stock underlying the SARS to satisfy the withholding tax obligation resulting from the exercise, using the closing stock price on February 26, 2018 of $86.30. Read SEC document |
| February 26, 2018 Filed Feb 27, 2018 02:14 UTC |
Alvarez JesusVP, General Manager, Mexico
|
Disposition to issuerCommon Stock | 1,779 | $86.30 | $153,527.70 |
DisclosureSEC source: 0001209191-18-013683 · doc4.xml · nonDerivative · entry 3 Alvarez Jesus · CIK 0001615466 · VP, General Manager, Mexico 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,235 F2 · kind: The reporting person received 97 shares of common stock upon the net exercise of 1,929 stock appreciation rights ("SARS"). The reporting person forfeited 1,779 shares of common stock underlying the SARS in payment of the exercise price and 53 shares of common stock underlying the SARS to satisfy the withholding tax obligation resulting from the exercise, using the closing stock price on February 26, 2018 of $86.30. Read SEC document |
| February 26, 2018 Filed Feb 27, 2018 02:14 UTC |
Alvarez JesusVP, General Manager, Mexico
|
Exercise / conversionCommon Stock | 1,929 | $79.58 | $153,509.82 |
DisclosureSEC source: 0001209191-18-013683 · doc4.xml · nonDerivative · entry 2 Alvarez Jesus · CIK 0001615466 · VP, General Manager, Mexico 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,014 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · kind: The reporting person received 97 shares of common stock upon the net exercise of 1,929 stock appreciation rights ("SARS"). The reporting person forfeited 1,779 shares of common stock underlying the SARS in payment of the exercise price and 53 shares of common stock underlying the SARS to satisfy the withholding tax obligation resulting from the exercise, using the closing stock price on February 26, 2018 of $86.30. Read SEC document |
| February 26, 2018 Filed Feb 27, 2018 02:14 UTC |
Alvarez JesusVP, General Manager, Mexico
|
GrantCommon Stock | 2,085 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-18-013683 · doc4.xml · nonDerivative · entry 1 Alvarez Jesus · CIK 0001615466 · VP, General Manager, Mexico 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,085 F1 · kind: Consists of restricted stock units ("RSU") under the Herbalife Ltd. 2014 Stock Incentive Plan. Each RSU represents a contingent right to receive one share of Herbalife Ltd. common stock on vesting. This award will vest 20% each on February 26, 2019 and February 26, 2020, and 60% on February 26, 2021. Read SEC document |
| February 26, 2018 Filed Feb 27, 2018 02:13 UTC |
Conchie StephenVP, Gen. Mgr. - Southeast Asia
|
GrantCommon Stock | 4,634 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-18-013682 · doc4.xml · nonDerivative · entry 1 Conchie Stephen · CIK 0001661500 · VP, Gen. Mgr. - Southeast Asia 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,634 F1 · kind: Consists of restricted stock units ("RSU") under the Herbalife Ltd. 2014 Stock Incentive Plan. Each RSU represents a contingent right to receive one share of Herbalife Ltd. common stock on vesting. This award will vest 20% each on February 26, 2019 and February 26, 2020, and 60% on February 26, 2021. Read SEC document |
| February 26, 2018 Filed Feb 27, 2018 15:32 UTC |
Montesino IbelisSVP/Managing Dir North America
|
GrantCommon Stock | 4,634 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-18-013734 · doc4.xml · nonDerivative · entry 1 Montesino Ibelis · CIK 0001513887 · SVP/Managing Dir North America 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,634 F1 · kind: Consists of restricted stock units ("RSU") under the Herbalife Ltd. 2014 Stock Incentive Plan. Each RSU represents a contingent right to receive one share of Herbalife Ltd. common stock on vesting. This award will vest 20% each on February 26, 2019 and February 26, 2020, and 60% on February 26, 2021. Read SEC document |
| February 26, 2018 Filed Mar 1, 2018 00:20 UTC |
Hienrich EdiSVP/Managing Director EMEA
|
Exercise / conversionStock Appreciation Rights · Derivative | 19,832 | $0.00 Strike: $22.94 | $0.00 |
DisclosureSEC source: 0001209191-18-014707 · doc4.xml · derivative · entry 5 Hienrich Edi · CIK 0001472187 · SVP/Managing Director EMEA 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 19,832 shares Expires 2020-05-07 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reporting person received 6,611 shares of common stock upon the net exercise of 19,832 stock appreciation rights ("SARS"). The reporting person forfeited 5,272 shares of common stock underlying the SARS in payment of the exercise price and 7,949 shares of common stock underlying the SARS to satisfy the withholding tax obligations resulting from the exercise, using the closing stock price on February 26, 2018 of $86.30. Read SEC document |
| February 26, 2018 Filed Mar 1, 2018 00:20 UTC |
Hienrich EdiSVP/Managing Director EMEA
|
Tax withholdingCommon Stock | 7,949 | $86.30 | $685,998.70 |
DisclosureSEC source: 0001209191-18-014707 · doc4.xml · nonDerivative · entry 3 Hienrich Edi · CIK 0001472187 · SVP/Managing Director EMEA 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,434 F1 · kind: The reporting person received 6,611 shares of common stock upon the net exercise of 19,832 stock appreciation rights ("SARS"). The reporting person forfeited 5,272 shares of common stock underlying the SARS in payment of the exercise price and 7,949 shares of common stock underlying the SARS to satisfy the withholding tax obligations resulting from the exercise, using the closing stock price on February 26, 2018 of $86.30. Read SEC document |
| February 26, 2018 Filed Mar 1, 2018 00:20 UTC |
Hienrich EdiSVP/Managing Director EMEA
|
Disposition to issuerCommon Stock | 5,242 | $86.30 | $452,384.60 |
DisclosureSEC source: 0001209191-18-014707 · doc4.xml · nonDerivative · entry 2 Hienrich Edi · CIK 0001472187 · SVP/Managing Director EMEA 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,383 F1 · kind: The reporting person received 6,611 shares of common stock upon the net exercise of 19,832 stock appreciation rights ("SARS"). The reporting person forfeited 5,272 shares of common stock underlying the SARS in payment of the exercise price and 7,949 shares of common stock underlying the SARS to satisfy the withholding tax obligations resulting from the exercise, using the closing stock price on February 26, 2018 of $86.30. Read SEC document |
| February 26, 2018 Filed Mar 1, 2018 00:20 UTC |
Hienrich EdiSVP/Managing Director EMEA
|
Exercise / conversionCommon Stock | 19,832 | $22.94 | $454,946.08 |
DisclosureSEC source: 0001209191-18-014707 · doc4.xml · nonDerivative · entry 1 Hienrich Edi · CIK 0001472187 · SVP/Managing Director EMEA 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,625 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reporting person received 6,611 shares of common stock upon the net exercise of 19,832 stock appreciation rights ("SARS"). The reporting person forfeited 5,272 shares of common stock underlying the SARS in payment of the exercise price and 7,949 shares of common stock underlying the SARS to satisfy the withholding tax obligations resulting from the exercise, using the closing stock price on February 26, 2018 of $86.30. Read SEC document |
| February 22, 2018 Filed Feb 27, 2018 02:32 UTC |
Hienrich EdiSVP/Managing Director EMEA
|
GrantStock Appreciation Rights · Derivative | 3,531 | $0.00 Strike: $57.19 | $0.00 |
DisclosureSEC source: 0001209191-18-013702 · doc4.xml · derivative · entry 6 Hienrich Edi · CIK 0001472187 · SVP/Managing Director EMEA 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,531 Underlying: Common Stock · 3,531 shares Expires 2027-02-27 F5 · kind: On February 27, 2017, the reporting person was granted an award of 17,655 SARs. The amount and timing of the vesting of these SARs is dependent upon the achievement by the Company of certain performance criteria for each of fiscal 2017, 2018 and 2019. The performance criteria for 2017 was met, resulting in 3,531 SARs which will vest on February 27, 2018. Read SEC document |
| February 22, 2018 Filed Feb 27, 2018 02:32 UTC |
Hienrich EdiSVP/Managing Director EMEA
|
GrantStock Appreciation Rights · Derivative | 3,359 | $0.00 Strike: $62.51 | $0.00 |
DisclosureSEC source: 0001209191-18-013702 · doc4.xml · derivative · entry 5 Hienrich Edi · CIK 0001472187 · SVP/Managing Director EMEA 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,718 Underlying: Common Stock · 3,359 shares Expires 2026-05-09 F4 · kind: On May 9, 2016, the reporting person was granted an award of 16,795 SARs. The amount and timing of the vesting of these SARs is dependent upon the achievement by the Company of certain performance criteria for each of fiscal 2016, 2017 and 2018. The performance criteria for 2017 was met, resulting in 3,359 SARs which will vest on May 9, 2018. Read SEC document |
| February 22, 2018 Filed Feb 27, 2018 02:32 UTC |
Hienrich EdiSVP/Managing Director EMEA
|
GrantStock Appreciation Rights · Derivative | 7,500 | $0.00 Strike: $47.80 | $0.00 |
DisclosureSEC source: 0001209191-18-013702 · doc4.xml · derivative · entry 4 Hienrich Edi · CIK 0001472187 · SVP/Managing Director EMEA 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,500 Underlying: Common Stock · 7,500 shares Expires 2025-05-07 F3 · kind: On May 7, 2015, the reporting person was granted an award of 12,500 SARs. The amount and timing of the vesting of these SARs is dependent upon the achievement by the Company of certain performance criteria for each of fiscal 2016, 2017 and 2018. The performance criteria for 2017 was met, resulting in 7,500 SARs which will vest on May 7, 2018. Read SEC document |
| February 22, 2018 Filed Feb 27, 2018 02:32 UTC |
Hienrich EdiSVP/Managing Director EMEA
|
GrantStock Appreciation Rights · Derivative | 19,576 | $0.00 Strike: $30.44 | $0.00 |
DisclosureSEC source: 0001209191-18-013702 · doc4.xml · derivative · entry 3 Hienrich Edi · CIK 0001472187 · SVP/Managing Director EMEA 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,626 Underlying: Common Stock · 19,576 shares Expires 2025-03-02 F2 · kind: On March 2, 2015, the reporting person was granted an award of 32,626 stock appreciation rights ("SARs"). The amount and timing of the vesting of these SARs is dependent upon the achievement by Herbalife Ltd. (the "Company") of certain performance criteria for each of fiscal 2015, 2016 and 2017. The performance criteria for 2017 was met, resulting in 19,576 SARs which will vest on March 2, 2018. Read SEC document |
| February 22, 2018 Filed Feb 27, 2018 02:23 UTC |
DeSimone JohnChief Financial Officer
|
GrantStock Appreciation Rights · Derivative | 12,253 | $0.00 Strike: $57.19 | $0.00 |
DisclosureSEC source: 0001209191-18-013698 · doc4.xml · derivative · entry 6 DeSimone John · CIK 0001463405 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,253 Underlying: Common Stock · 12,253 shares Expires 2027-02-27 F6 · kind: On February 27, 2017, the reporting person was granted an award of 61,264 SARs. The amount and timing of the vesting of these SARs is dependent upon the achievement by the Company of certain performance criteria for each of fiscal 2017, 2018 and 2019. The performance criteria for 2017 was met, resulting in 12,253 SARs which will vest on February 27, 2018. Read SEC document |
| February 22, 2018 Filed Feb 27, 2018 02:23 UTC |
DeSimone JohnChief Financial Officer
|
GrantStock Appreciation Rights · Derivative | 11,656 | $0.00 Strike: $62.51 | $0.00 |
DisclosureSEC source: 0001209191-18-013698 · doc4.xml · derivative · entry 5 DeSimone John · CIK 0001463405 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,312 Underlying: Common Stock · 11,656 shares Expires 2026-05-09 F5 · kind: On May 9, 2016, the reporting person was granted an award of 58,280 SARs. The amount and timing of the vesting of these SARs is dependent upon the achievement by the Company of certain performance criteria for each of fiscal 2016, 2017 and 2018. The performance criteria for 2017 was met, resulting in 11,656 SARs which will vest on May 9, 2018. Read SEC document |
| February 22, 2018 Filed Feb 27, 2018 02:23 UTC |
DeSimone JohnChief Financial Officer
|
GrantStock Appreciation Rights · Derivative | 30,000 | $0.00 Strike: $47.80 | $0.00 |
DisclosureSEC source: 0001209191-18-013698 · doc4.xml · derivative · entry 4 DeSimone John · CIK 0001463405 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 30,000 shares Expires 2025-05-07 F4 · kind: On May 7, 2015, the reporting person was granted an award of 50,000 SARs. The amount and timing of the vesting of these SARs is dependent upon the achievement by the Company of certain performance criteria for each of fiscal 2016, 2017 and 2018. The performance criteria for 2017 was met, resulting in 30,000 SARs which will vest on May 7, 2018. Read SEC document |
| February 22, 2018 Filed Feb 27, 2018 02:23 UTC |
DeSimone JohnChief Financial Officer
|
GrantStock Appreciation Rights · Derivative | 53,834 | $0.00 Strike: $30.44 | $0.00 |
DisclosureSEC source: 0001209191-18-013698 · doc4.xml · derivative · entry 3 DeSimone John · CIK 0001463405 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 89,722 Underlying: Common Stock · 53,834 shares Expires 2025-03-02 F3 · kind: On March 2, 2015, the reporting person was granted an award of 89,722 stock appreciation rights ("SARs"). The amount and timing of the vesting of these SARs is dependent upon the achievement by Herbalife Ltd. (the "Company") of certain performance criteria for each of fiscal 2015, 2016 and 2017. The performance criteria for 2017 was met, resulting in 53,834 SARs which will vest on March 2, 2018. Read SEC document |
| February 22, 2018 Filed Feb 27, 2018 02:22 UTC |
Harms ThomasSVP, China & APAC
|
GrantStock Appreciation Rights · Derivative | 635 | $0.00 Strike: $57.19 | $0.00 |
DisclosureSEC source: 0001209191-18-013696 · doc4.xml · derivative · entry 4 Harms Thomas · CIK 0001713357 · SVP, China & APAC 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 635 Underlying: Common Stock · 635 shares Expires 2027-02-27 F4 · kind: On February 27, 2017, the reporting person was granted an award of 3,177 SARs. The amount and timing of the vesting of these SARs is dependent upon the achievement by the Company of certain performance criteria for each of fiscal 2017, 2018 and 2019. The performance criteria for 2017 was met, resulting in 635 SARs which will vest on February 27, 2018. Read SEC document |
| February 22, 2018 Filed Feb 27, 2018 02:22 UTC |
Harms ThomasSVP, China & APAC
|
GrantStock Appreciation Rights · Derivative | 605 | $0.00 Strike: $62.51 | $0.00 |
DisclosureSEC source: 0001209191-18-013696 · doc4.xml · derivative · entry 3 Harms Thomas · CIK 0001713357 · SVP, China & APAC 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,209 Underlying: Common Stock · 605 shares Expires 2026-05-09 F3 · kind: On May 9, 2016, the reporting person was granted an award of 3,023 SARs. The amount and timing of the vesting of these SARs is dependent upon the achievement by the Company of certain performance criteria for each of fiscal 2016, 2017 and 2018. The performance criteria for 2017 was met, resulting in 605 SARs which will vest on May 9, 2018. Read SEC document |
| February 22, 2018 Filed Feb 27, 2018 02:22 UTC |
Harms ThomasSVP, China & APAC
|
GrantStock Appreciation Rights · Derivative | 5,506 | $0.00 Strike: $30.44 | $0.00 |
DisclosureSEC source: 0001209191-18-013696 · doc4.xml · derivative · entry 2 Harms Thomas · CIK 0001713357 · SVP, China & APAC 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,176 Underlying: Common Stock · 5,506 shares Expires 2025-03-02 F2 · kind: On March 2, 2015, the reporting person was granted an award of 9,176 stock appreciation rights ("SARs"). The amount and timing of the vesting of these SARs is dependent upon the achievement by Herbalife Ltd. (the "Company") of certain performance criteria for each of fiscal 2015, 2016 and 2017. The performance criteria for 2017 was met, resulting in 5,506 SARs which will vest on March 2, 2018. Read SEC document |
| February 22, 2018 Filed Feb 27, 2018 02:21 UTC |
Aspauza JossieVP, SAM/CAM
|
GrantStock Appreciation Rights · Derivative | 1,102 | $0.00 Strike: $57.19 | $0.00 |
DisclosureSEC source: 0001209191-18-013695 · doc4.xml · derivative · entry 4 Aspauza Jossie · CIK 0001624298 · VP, SAM/CAM 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,102 Underlying: Common Stock · 1,102 shares Expires 2027-02-27 F4 · kind: On February 27, 2017, the reporting person was granted an award of 5,508 SARs. The amount and timing of the vesting of these SARs is dependent upon the achievement by the Company of certain performance criteria for each of fiscal 2017, 2018 and 2019. The performance criteria for 2017 was met, resulting in 1,102 SARs which will vest on February 27, 2018. Read SEC document |
| February 22, 2018 Filed Feb 27, 2018 02:21 UTC |
Aspauza JossieVP, SAM/CAM
|
GrantStock Appreciation Rights · Derivative | 1,048 | $0.00 Strike: $62.51 | $0.00 |
DisclosureSEC source: 0001209191-18-013695 · doc4.xml · derivative · entry 3 Aspauza Jossie · CIK 0001624298 · VP, SAM/CAM 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,096 Underlying: Common Stock · 1,048 shares Expires 2026-05-09 F3 · kind: On May 9, 2016, the reporting person was granted an award of 5,240 SARs. The amount and timing of the vesting of these SARs is dependent upon the achievement by the Company of certain performance criteria for each of fiscal 2016, 2017 and 2018. The performance criteria for 2017 was met, resulting in 1,048 SARs which will vest on May 9, 2018. Read SEC document |
| February 22, 2018 Filed Feb 27, 2018 02:21 UTC |
Aspauza JossieVP, SAM/CAM
|
GrantStock Appreciation Rights · Derivative | 5,873 | $0.00 Strike: $30.44 | $0.00 |
DisclosureSEC source: 0001209191-18-013695 · doc4.xml · derivative · entry 2 Aspauza Jossie · CIK 0001624298 · VP, SAM/CAM 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,873 Underlying: Common Stock · 5,873 shares Expires 2025-03-02 F2 · kind: On March 2, 2015, the reporting person was granted an award of 9,787 stock appreciation rights ("SARs"). The amount and timing of the vesting of these SARs is dependent upon the achievement by Herbalife Ltd. (the "Company") of certain performance criteria for each of fiscal 2015, 2016 and 2017. The performance criteria for 2017 was met, resulting in 5,873 SARs which will vest on March 2, 2018. Read SEC document |
| February 22, 2018 Filed Feb 27, 2018 02:21 UTC |
Hoffman Alan LEVP, Global Corporate Affairs
|
GrantStock Appreciation Rights · Derivative | 4,590 | $0.00 Strike: $57.19 | $0.00 |
DisclosureSEC source: 0001209191-18-013694 · doc4.xml · derivative · entry 4 Hoffman Alan L · CIK 0001624527 · EVP, Global Corporate Affairs 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,590 Underlying: Common Stock · 4,590 shares Expires 2027-02-27 F4 · kind: On February 27, 2017, the reporting person was granted an award of 22,951 SARs. The amount and timing of the vesting of these SARs is dependent upon the achievement by the Company of certain performance criteria for each of fiscal 2017, 2018 and 2019. The performance criteria for 2017 was met, resulting in 4,590 SARs which will vest on February 27, 2018. Read SEC document |
| February 22, 2018 Filed Feb 27, 2018 02:21 UTC |
Hoffman Alan LEVP, Global Corporate Affairs
|
GrantStock Appreciation Rights · Derivative | 4,367 | $0.00 Strike: $62.51 | $0.00 |
DisclosureSEC source: 0001209191-18-013694 · doc4.xml · derivative · entry 3 Hoffman Alan L · CIK 0001624527 · EVP, Global Corporate Affairs 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,734 Underlying: Common Stock · 4,367 shares Expires 2026-05-09 F3 · kind: On May 9, 2016, the reporting person was granted an award of 21,834 SARs. The amount and timing of the vesting of these SARs is dependent upon the achievement by the Company of certain performance criteria for each of fiscal 2016, 2017 and 2018. The performance criteria for 2017 was met, resulting in 4,367 SARs which will vest on May 9, 2018. Read SEC document |
| February 22, 2018 Filed Feb 27, 2018 02:21 UTC |
Hoffman Alan LEVP, Global Corporate Affairs
|
GrantStock Appreciation Rights · Derivative | 31,811 | $0.00 Strike: $30.44 | $0.00 |
DisclosureSEC source: 0001209191-18-013694 · doc4.xml · derivative · entry 2 Hoffman Alan L · CIK 0001624527 · EVP, Global Corporate Affairs 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 53,017 Underlying: Common Stock · 31,811 shares Expires 2025-03-02 F2 · kind: On March 2, 2015, the reporting person was granted an award of 53,017 stock appreciation rights ("SARs"). The amount and timing of the vesting of these SARs is dependent upon the achievement by Herbalife Ltd. (the "Company") of certain performance criteria for each of fiscal 2015, 2016 and 2017. The performance criteria for 2017 was met, resulting in 31,811 SARs which will vest on March 2, 2018. Read SEC document |
| February 22, 2018 Filed Feb 27, 2018 02:20 UTC |
PEZZULLO DAVIDChief Operating Officer
|
GrantStock Appreciation Rights · Derivative | 4,590 | $0.00 Strike: $57.19 | $0.00 |
DisclosureSEC source: 0001209191-18-013693 · doc4.xml · derivative · entry 4 PEZZULLO DAVID · CIK 0001311282 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,590 Underlying: Common Stock · 4,590 shares Expires 2027-02-27 F4 · kind: On February 27, 2017, the reporting person was granted an award of 22,951 SARs. The amount and timing of the vesting of these SARs is dependent upon the achievement by the Company of certain performance criteria for each of fiscal 2017, 2018 and 2019. The performance criteria for 2017 was met, resulting in 4,590 SARs which will vest on February 27, 2018. Read SEC document |
| February 22, 2018 Filed Feb 27, 2018 02:20 UTC |
PEZZULLO DAVIDChief Operating Officer
|
GrantStock Appreciation Rights · Derivative | 4,367 | $0.00 Strike: $62.51 | $0.00 |
DisclosureSEC source: 0001209191-18-013693 · doc4.xml · derivative · entry 3 PEZZULLO DAVID · CIK 0001311282 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,734 Underlying: Common Stock · 4,367 shares Expires 2026-05-09 F3 · kind: On May 9, 2016, the reporting person was granted an award of 21,834 SARs. The amount and timing of the vesting of these SARs is dependent upon the achievement by the Company of certain performance criteria for each of fiscal 2016, 2017 and 2018. The performance criteria for 2017 was met, resulting in 4,367 SARs which will vest on May 9, 2018. Read SEC document |
| February 22, 2018 Filed Feb 27, 2018 02:20 UTC |
PEZZULLO DAVIDChief Operating Officer
|
GrantStock Appreciation Rights · Derivative | 31,811 | $0.00 Strike: $30.44 | $0.00 |
DisclosureSEC source: 0001209191-18-013693 · doc4.xml · derivative · entry 2 PEZZULLO DAVID · CIK 0001311282 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 53,017 Underlying: Common Stock · 31,811 shares Expires 2025-03-02 F2 · kind: On March 2, 2015, the reporting person was granted an award of 53,017 stock appreciation rights ("SARs"). The amount and timing of the vesting of these SARs is dependent upon the achievement by Herbalife Ltd. (the "Company") of certain performance criteria for each of fiscal 2015, 2016 and 2017. The performance criteria for 2017 was met, resulting in 31,811 SARs which will vest on March 2, 2018. Read SEC document |
| February 22, 2018 Filed Feb 27, 2018 02:19 UTC |
Schissel Mark JEVP, WW Operations
|
GrantStock Appreciation Rights · Derivative | 1,218 | $0.00 Strike: $57.19 | $0.00 |
DisclosureSEC source: 0001209191-18-013692 · doc4.xml · derivative · entry 4 Schissel Mark J · CIK 0001713270 · EVP, WW Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,218 Underlying: Common Stock · 1,218 shares Expires 2027-02-27 F4 · kind: On February 27, 2017, the reporting person was granted an award of 6,091 SARs. The amount and timing of the vesting of these SARs is dependent upon the achievement by the Company of certain performance criteria for each of fiscal 2017, 2018 and 2019. The performance criteria for 2017 was met, resulting in 1,218 SARs which will vest on February 27, 2018. Read SEC document |
| February 22, 2018 Filed Feb 27, 2018 02:19 UTC |
Schissel Mark JEVP, WW Operations
|
GrantStock Appreciation Rights · Derivative | 1,260 | $0.00 Strike: $62.51 | $0.00 |
DisclosureSEC source: 0001209191-18-013692 · doc4.xml · derivative · entry 3 Schissel Mark J · CIK 0001713270 · EVP, WW Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,260 Underlying: Common Stock · 1,260 shares Expires 2026-05-09 F3 · kind: On May 9, 2016, the reporting person was granted an award of 6,298 SARs. The amount and timing of the vesting of these SARs is dependent upon the achievement by the Company of certain performance criteria for each of fiscal 2016, 2017 and 2018. The performance criteria for 2017 was met, resulting in 1,260 SARs which will vest on May 9, 2018. Read SEC document |
| February 22, 2018 Filed Feb 27, 2018 02:19 UTC |
Schissel Mark JEVP, WW Operations
|
GrantStock Appreciation Rights · Derivative | 8,442 | $0.00 Strike: $30.44 | $0.00 |
DisclosureSEC source: 0001209191-18-013692 · doc4.xml · derivative · entry 2 Schissel Mark J · CIK 0001713270 · EVP, WW Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,442 Underlying: Common Stock · 8,442 shares Expires 2025-03-02 F2 · kind: On March 2, 2015, the reporting person was granted an award of 14,070 stock appreciation rights ("SARs"). The amount and timing of the vesting of these SARs is dependent upon the achievement by Herbalife Ltd. (the "Company") of certain performance criteria for each of fiscal 2015, 2016 and 2017. The performance criteria for 2017 was met, resulting in 8,442 SARs which will vest on March 2, 2018. Read SEC document |
| February 22, 2018 Filed Feb 27, 2018 02:19 UTC |
Lamberti FrankEVP, Dist/Customer Experience
|
GrantStock Appreciation Rights · Derivative | 3,531 | $0.00 Strike: $57.19 | $0.00 |
DisclosureSEC source: 0001209191-18-013691 · doc4.xml · derivative · entry 5 Lamberti Frank · CIK 0001661501 · EVP, Dist/Customer Experience 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,531 Underlying: Common Stock · 3,531 shares Expires 2027-02-27 F5 · kind: On February 27, 2017, the reporting person was granted an award of 17,655 SARs. The amount and timing of the vesting of these SARs is dependent upon the achievement by the Company of certain performance criteria for each of fiscal 2017, 2018 and 2019. The performance criteria for 2017 was met, resulting in 3,531 SARs which will vest on February 27, 2018. Read SEC document |
| February 22, 2018 Filed Feb 27, 2018 02:19 UTC |
Lamberti FrankEVP, Dist/Customer Experience
|
GrantStock Appreciation Rights · Derivative | 3,359 | $0.00 Strike: $62.51 | $0.00 |
DisclosureSEC source: 0001209191-18-013691 · doc4.xml · derivative · entry 4 Lamberti Frank · CIK 0001661501 · EVP, Dist/Customer Experience 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,718 Underlying: Common Stock · 3,359 shares Expires 2026-05-09 F4 · kind: On May 9, 2016, the reporting person was granted an award of 16,795 SARs. The amount and timing of the vesting of these SARs is dependent upon the achievement by the Company of certain performance criteria for each of fiscal 2016, 2017 and 2018. The performance criteria for 2017 was met, resulting in 3,359 SARs which will vest on May 9, 2018. Read SEC document |
| February 22, 2018 Filed Feb 27, 2018 02:19 UTC |
Lamberti FrankEVP, Dist/Customer Experience
|
GrantStock Appreciation Rights · Derivative | 1,567 | $0.00 Strike: $54.75 | $0.00 |
DisclosureSEC source: 0001209191-18-013691 · doc4.xml · derivative · entry 3 Lamberti Frank · CIK 0001661501 · EVP, Dist/Customer Experience 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,134 Underlying: Common Stock · 1,567 shares Expires 2026-02-28 F3 · kind: On February 28,2016, the reporting person was granted an award of 7,837 stock appreciation rights ("SARs"). The amount and timing of the vesting of these SARs is dependent upon the achievement by Herbalife Ltd. (the "Company") of certain performance criteria for each of fiscal 2015, 2016 and 2017. The performance criteria for 2017 was met, resulting in 1,567 SARs which will vest on February 28, 2018. Read SEC document |
| February 22, 2018 Filed Feb 27, 2018 02:19 UTC |
Lamberti FrankEVP, Dist/Customer Experience
|
GrantStock Appreciation Rights · Derivative | 8,442 | $0.00 Strike: $30.44 | $0.00 |
DisclosureSEC source: 0001209191-18-013691 · doc4.xml · derivative · entry 2 Lamberti Frank · CIK 0001661501 · EVP, Dist/Customer Experience 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,070 Underlying: Common Stock · 8,442 shares Expires 2025-03-02 F2 · kind: On March 2, 2015, the reporting person was granted an award of 14,070 stock appreciation rights ("SARs"). The amount and timing of the vesting of these SARs is dependent upon the achievement by Herbalife Ltd. (the "Company") of certain performance criteria for each of fiscal 2015, 2016 and 2017. The performance criteria for 2017 was met, resulting in 8,442 which will vest on March 2, 2018. Read SEC document |
| February 22, 2018 Filed Feb 27, 2018 02:18 UTC |
Walsh DesPresident
|
GrantStock Appreciation Rights · Derivative | 12,754 | $0.00 Strike: $57.19 | $0.00 |
DisclosureSEC source: 0001209191-18-013690 · doc4.xml · derivative · entry 4 Walsh Des · CIK 0001373040 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,754 Underlying: Common Stock · 12,754 shares Expires 2027-02-27 F4 · kind: On February 27, 2017, the reporting person was granted an award of 63,771 SARs. The amount and timing of the vesting of these SARs is dependent upon the achievement by the Company of certain performance criteria for each of fiscal 2017, 2018 and 2019. The performance criteria for 2017 was met, resulting in 12,754 SARs which will vest on February 27, 2018. Read SEC document |
| February 22, 2018 Filed Feb 27, 2018 02:18 UTC |
Walsh DesPresident
|
GrantStock Appreciation Rights · Derivative | 12,133 | $0.00 Strike: $62.51 | $0.00 |
DisclosureSEC source: 0001209191-18-013690 · doc4.xml · derivative · entry 3 Walsh Des · CIK 0001373040 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,266 Underlying: Common Stock · 12,133 shares Expires 2026-05-09 F3 · kind: On May 9, 2016, the reporting person was granted an award of 60,665 SARs. The amount and timing of the vesting of these SARs is dependent upon the achievement by the Company of certain performance criteria for each of fiscal 2016, 2017 and 2018. The performance criteria for 2017 was met, resulting in 12,133 SARs which will vest on May 9, 2018. Read SEC document |
| February 22, 2018 Filed Feb 27, 2018 02:18 UTC |
Walsh DesPresident
|
GrantStock Appreciation Rights · Derivative | 49,950 | $0.00 Strike: $47.80 | $0.00 |
DisclosureSEC source: 0001209191-18-013690 · doc4.xml · derivative · entry 2 Walsh Des · CIK 0001373040 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 66,760 Underlying: Common Stock · 49,950 shares Expires 2025-05-07 F2 · kind: On May 7, 2015, the reporting person was granted an award of 66,760 SARs. The amount and timing of the vesting of these SARs is dependent upon the achievement by the Company of certain performance criteria for each of fiscal 2016, 2017 and 2018. The performance criteria for 2017 was met, resulting in 49,950 SARs which will vest on May 7, 2018. Read SEC document |
| February 22, 2018 Filed Feb 27, 2018 02:18 UTC |
Walsh DesPresident
|
GrantStock Appreciation Rights · Derivative | 73,409 | $0.00 Strike: $30.44 | $0.00 |
DisclosureSEC source: 0001209191-18-013690 · doc4.xml · derivative · entry 1 Walsh Des · CIK 0001373040 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 122,349 Underlying: Common Stock · 73,409 shares Expires 2025-03-02 F1 · kind: On March 2, 2015, the reporting person was granted an award of 122,349 stock appreciation rights ("SARs"). The amount and timing of the vesting of these SARs is dependent upon the achievement by Herbalife Ltd. (the "Company") of certain performance criteria for each of fiscal 2015, 2016 and 2017. The performance criteria for 2017 was met, resulting in 73,409 SARs which will vest on March 2, 2018. Read SEC document |
| February 22, 2018 Filed Feb 27, 2018 02:17 UTC |
JOHNSON MICHAELDirector · Executive Chairman
|
GrantStock Appreciation Rights · Derivative | 17,655 | $0.00 Strike: $57.19 | $0.00 |
DisclosureSEC source: 0001209191-18-013689 · doc4.xml · derivative · entry 3 JOHNSON MICHAEL · CIK 0001311173 · Director · Executive Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,655 Underlying: Common Stock · 17,655 shares Expires 2027-02-27 F3 · kind: On February 27, 2017, the reporting person was granted an award of 88,276 SARs. The amount and timing of the vesting of these SARs is dependent upon the achievement by the Company of certain performance criteria for each of fiscal 2017, 2018 and 2019. The performance criteria for 2017 was met, resulting in 17,655 SARs which will vest on February 27, 2018. Read SEC document |
| February 22, 2018 Filed Feb 27, 2018 02:17 UTC |
JOHNSON MICHAELDirector · Executive Chairman
|
GrantStock Appreciation Rights · Derivative | 33,591 | $0.00 Strike: $47.80 | $0.00 |
DisclosureSEC source: 0001209191-18-013689 · doc4.xml · derivative · entry 2 JOHNSON MICHAEL · CIK 0001311173 · Director · Executive Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 67,182 Underlying: Common Stock · 33,591 shares Expires 2026-05-09 F2 · kind: On May 9, 2016, the reporting person was granted an award of 167,954 SARs. The amount and timing of the vesting of these SARs is dependent upon the achievement by the Company of certain performance criteria for each of fiscal 2016, 2017 and 2018. The performance criteria for 2017 was met, resulting in 33,951 SARs which will vest on May 9, 2018. Read SEC document |
| February 22, 2018 Filed Feb 27, 2018 02:17 UTC |
JOHNSON MICHAELDirector · Executive Chairman
|
GrantStock Appreciation Rights · Derivative | 244,698 | $0.00 Strike: $30.44 | $0.00 |
DisclosureSEC source: 0001209191-18-013689 · doc4.xml · derivative · entry 1 JOHNSON MICHAEL · CIK 0001311173 · Director · Executive Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 407,830 Underlying: Common Stock · 244,698 shares Expires 2025-03-02 F1 · kind: On March 2, 2015, the reporting person was granted an award of 407,830 stock appreciation rights ("SARs"). The amount and timing of the vesting of these SARs is dependent upon the achievement by Herbalife Ltd. (the "Company") of certain performance criteria for each of fiscal 2015, 2016 and 2017. The performance criteria for 2017 was met, resulting in 244,698 SARs which will vest on March 2, 2018. Read SEC document |
| February 22, 2018 Filed Feb 27, 2018 02:16 UTC |
LEVY ROBERTEVP, The Americas
|
GrantStock Appreciation Rights · Derivative | 4,590 | $0.00 Strike: $57.19 | $0.00 |
DisclosureSEC source: 0001209191-18-013687 · doc4.xml · derivative · entry 4 LEVY ROBERT · CIK 0001311283 · EVP, The Americas 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,590 Underlying: Common Stock · 4,590 shares Expires 2027-02-27 F4 · kind: On February 27, 2017, the reporting person was granted an award of 22,951 SARs. The amount and timing of the vesting of these SARs is dependent upon the achievement by the Company of certain performance criteria for each of fiscal 2017, 2018 and 2019. The performance criteria for 2017 was met, resulting in 4,590 SARs which will vest on February 27, 2018. Read SEC document |
| February 22, 2018 Filed Feb 27, 2018 02:16 UTC |
LEVY ROBERTEVP, The Americas
|
GrantStock Appreciation Rights · Derivative | 4,367 | $0.00 Strike: $62.51 | $0.00 |
DisclosureSEC source: 0001209191-18-013687 · doc4.xml · derivative · entry 3 LEVY ROBERT · CIK 0001311283 · EVP, The Americas 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,734 Underlying: Common Stock · 4,367 shares Expires 2026-05-09 F3 · kind: On May 9, 2016, the reporting person was granted an award of 21,834 SARs. The amount and timing of the vesting of these SARs is dependent upon the achievement by the Company of certain performance criteria for each of fiscal 2016, 2017 and 2018. The performance criteria for 2017 was met, resulting in 4,367 SARs which will vest on May 9, 2018. Read SEC document |
| February 22, 2018 Filed Feb 27, 2018 02:16 UTC |
LEVY ROBERTEVP, The Americas
|
GrantStock Appreciation Rights · Derivative | 31,811 | $0.00 Strike: $30.44 | $0.00 |
DisclosureSEC source: 0001209191-18-013687 · doc4.xml · derivative · entry 2 LEVY ROBERT · CIK 0001311283 · EVP, The Americas 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 53,017 Underlying: Common Stock · 31,811 shares Expires 2025-03-02 F2 · kind: On March 2, 2015, the reporting person was granted an award of 53,017 stock appreciation rights ("SARs"). The amount and timing of the vesting of these SARs is dependent upon the achievement by Herbalife Ltd. (the "Company") of certain performance criteria for each of fiscal 2015, 2016 and 2017. The performance criteria for 2017 was met, resulting in 31,811 SARs which will vest on March 2, 2018. Read SEC document |
| February 22, 2018 Filed Feb 27, 2018 02:16 UTC |
Chiu Shin-Shing BoscoPrincipal Accounting Officer
|
GrantStock Appreciation Rights · Derivative | 1,624 | $0.00 Strike: $57.19 | $0.00 |
DisclosureSEC source: 0001209191-18-013686 · doc4.xml · derivative · entry 5 Chiu Shin-Shing Bosco · CIK 0001504597 · Principal Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,624 Underlying: Common Stock · 1,624 shares Expires 2027-02-27 F5 · kind: On February 27, 2017, the reporting person was granted an award of 8,121 SARs. The amount and timing of the vesting of these SARs is dependent upon the achievement by the Company of certain performance criteria for each of fiscal 2017, 2018 and 2019. The performance criteria for 2017 was met, resulting in 1,624 SARs which will vest on February 27, 2018. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.